Abstract
Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51%) showed decreased C-peptide concentrations, of whom 20% showed a decrease of ≥50%. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4%) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.
| Original language | English |
|---|---|
| Pages (from-to) | 1033-1042 |
| Number of pages | 10 |
| Journal | Diabetes Technology and Therapeutics |
| Volume | 14 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2012 Nov 1 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Medical Laboratory Technology
Cite this
The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus. / Shin, Mi Seon; Yu, Ji Hee; Jung, Chang Hee; Hwang, Jenie Yoonoo; Lee, Woo Je; Kim, Min Seon; Park, Joong Yeol.
In: Diabetes Technology and Therapeutics, Vol. 14, No. 11, 01.11.2012, p. 1033-1042.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus
AU - Shin, Mi Seon
AU - Yu, Ji Hee
AU - Jung, Chang Hee
AU - Hwang, Jenie Yoonoo
AU - Lee, Woo Je
AU - Kim, Min Seon
AU - Park, Joong Yeol
PY - 2012/11/1
Y1 - 2012/11/1
N2 - Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51%) showed decreased C-peptide concentrations, of whom 20% showed a decrease of ≥50%. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4%) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.
AB - Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51%) showed decreased C-peptide concentrations, of whom 20% showed a decrease of ≥50%. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4%) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.
UR - http://www.scopus.com/inward/record.url?scp=84868020758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868020758&partnerID=8YFLogxK
U2 - 10.1089/dia.2012.0144
DO - 10.1089/dia.2012.0144
M3 - Article
C2 - 22958196
AN - SCOPUS:84868020758
VL - 14
SP - 1033
EP - 1042
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
SN - 1520-9156
IS - 11
ER -